Rheumatoid Arthritis Therapeutics Market Size, Trends [2031]

Report Description

Rheumatoid Arthritis Therapeutics Market Outlook 2031

The Global Rheumatoid Arthritis Therapeutics Market size was valued at USD 29.88 Billion in 2022 and is likely reach to USD 44.94 Billion by 2031, expanding at a CAGR of 4.64% during the forecast period, 2023–2031. The growth of the market is attributed to the rising prevalence of arthritis, improved treatment methods, favorable government initiatives, and rising awareness among the population.

Get Free Sample Report

Rheumatoid arthritis (RA) is basically an immune system malfunctioning, a blistering condition that causes ongoing torment, expanding, and disaster in the functioning capacity of joints. It significantly occurs when a person’s immune system attacks his own cells of synovium. The synovium is inside coating of layers which fundamentally covers or protects the joints.

The destruction of synovium causes pain in the joints and difficulty in movement. The symptoms of RA includes stiffness in joints, aching or pain in more than one joint, swelling and tenderness in joints, fever, fatigue or tiredness, weight loss, and weakness.

RA can impact other tissues of the body and cause disorders in organs such as the heart, lungs, and eyes. The risk factors for RA are obesity, smoking, genetic inheritance, and old age.

According to the Centre for Disease Control and Prevention (CDC), in 2013–2015, around 54 million US adults, which was 22.7% of total population per year suffered from some kind of arthritis, lupus, rheumatoid arthritis, gout, or fibromyalgia.

The same report estimated that till 2040, an around 78 million, representing 26% of US adults of age 18 years or more are projected to get diagnosed with arthritis. This high prevalence rate is likely boost the market in the near future.

The COVID-19 pandemic has brought huge impact on global market with restrictions and nationwide lockdowns worldwide. The RA market also witnessed negative impact due to the high burden of the coronavirus cases on the healthcare sector and reduced focus on other disease treatment as well as management.

This market gained some momentum back with relaxing restriction and improving healthcare sector after the pandemic as government began to bolster their healthcare for the future events.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing demand for biologics along with rising numbers of generic drugs and FDA approvals for the treatment of rheumatoid arthritis is propelling the market growth. 
• High prevalence of the disease, increasing governments support, and management of disease along with surge in flow of funding for research and development activities are driving the overall market growth.  
• Favorable reimbursement policies, robust clinical pipeline, and well developed healthcare infrastructure are the key factors expected to boost the market expansion in the coming future.
• High cost of biologics and accessibility to these biologics are key factors likely to hinder the market growth in the upcoming years.
• Lack of proper healthcare facilities in some poor countries, low research activities and approval rate in the underdeveloped nations can be major restraints to the market.
• Large untapped population, high prevalence of the disease, and increasing health awareness among the population prove to be creating a huge opportunity in the market expansion during the forecast period.

Scope of Rheumatoid Arthritis Therapeutics Market Report

The report on the global rheumatoid arthritis therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Rheumatoid Arthritis Therapeutics Market Segment Insights

Biopharmaceutical segment is expected to grow at a rapid pace

Based on molecules, the global rheumatoid arthritis therapeutics market is bifurcated into pharmaceutical and biopharmaceutical. The pharmaceutical segment is further divided into NSAIDS, analgesics, DMARDs, and glucocorticoids. The biopharmaceutical segment is sub-classified into biologics and biosimilars.

The biologics segment is further segmented into TNF-α antagonists, T-cell inhibitors, CD20 antigen, JAK inhibitors, and anti-IL6 biologics. Additionally, the biosimilars segment is bifurcated into CD20 antigen and TNF-α antagonists.

The biopharmaceutical segment is expected to grow at a rapid pace during the forecast period attributing to the high efficiency of the treatment. The biologics are more in demand than the biosimilars as the doctors prefer biologics.

Biologic drugs are anticipated to hold a major revenue share in developed markets in the coming future. However, in developing economies such as Mexico, Brazil, and South Africa, these drugs face several challenges from pharmaceutical generics and biosimilars due to expensive biologics in the market.

The biosimilars segment is expected to exhibit a considerable growth rate in the near future as these drugs are cheap, easily available, and demonstrate high efficiency in terms of results. Due to launch of new products in the segment, biosimilars are gaining popularity in the developed nations as well and the developing nations are preferring biosimilars due to its cheap price.

The pharmaceutical segment is the first-line of treatment for RA. So, this segment is also growing at a good pace. With new developments and technological advancement in the segment the market is set to grow at considerable rate.

Get Free Sample Report

Prescription segment is projected to expand at a considerable CAGR

On the basis of sales channel, the market is bifurcated into prescription and over-the-counter (OTC). The prescription segment is projected to expand at a considerable CAGR owing to the growing awareness among the people regarding the need of prescribed by the doctor to avoid worsening of the disease or side-effect of the drugs.

As prolonged use of RA drugs sometimes results in drug resistance, due to which patients suffering from this disease are expected to consult rheumatologists and follow prescribed drugs. Moreover, there are inadequate number of OTC products available, which makes the prescribed drugs to dominate in the coming future.

The OTC products has various disadvantages which is proving to be working in the negative direction for the segment. The OTC drugs have various adverse effects if used for long term as well as there are new drug development in the field with less side effects. So these factors are affecting the market segment in future market growth.

Get Free Sample Report

Rheumatoid Arthritis Therapeutics Market Regional Outlook

North America is anticipated to constitute a major market share

In terms of regions, the global rheumatoid arthritis therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of the North America is anticipated to constitute a major market share in the coming years. 

Improved awareness of disease therapies among patients, rising prevalence of RA, and high public and non-government organization on healthcare expenditure are pushing the growth of the regional market.

Additionally, favorable reimbursement policies, easy access to quality healthcare, strong clinical pipeline, and approval of novel drugs are anticipated to encourage the overall revenue share of North America.

Meanwhile, Asia Pacific is a promising region for substantial growth during the forecast period. The huge population and changing lifestyle of a large number of population are proving to be key factors for high spending on healthcare. Along with new product developments, the rising healthcare expenses is boosting the regional market growth in the near future.

Get Free Sample Report